All Episodes

Episode 111 – The Growth Rocketship: The Future of Rewards-Based Advertising With Fetch

Episode 110 – Spotlight on US State Healthcare Transaction Review Laws

Episode 109 – Drug Pricing and Market Access: Key Takeaways From 2025 and Outlook for 2026

Episode 108 – UK FinReg Focus Areas in 2026

Episode 107 – Drug Pricing and Market Access: "Think of It as a Loop" — Succeeding in an Evolving Policy Landscape

Episode 106 – The FDA's New Playbook: Biosimilars, National Priority Vouchers, and the Plausible Mechanism Pathway

Episode 105 – Drug Pricing and Market Access: Government Pricing Assessment Expectations and Benefits

Episode 104 – Drug Pricing and Market Access: Deep Dive on the FDA Commissioner's National Priority Voucher Program Awards

Episode 103 – Drug Pricing: Takeaways from the Chicago Medicaid Drug Rebate Program Summit

Episode 102 – EU Data Act: Spotlight on Switching Requirements for Data Processing Services

Episode 101 – EU Data Act: Implications for Data Privacy and Cybersecurity

Episode 100 – The Leeds Reforms: Implications for UK Financial Services

Episode 99 – Drug Pricing: Takeaways from the Philadelphia Pricing and Contracting USA Conference

Episode 98 – Drug Pricing: Takeaways from the MDMA Annual Meeting

Episode 97 – Drug Pricing: How the Drug Pricing EO Impacts FDA and Overlaps with Grassley-Led Legislation

Episode 96 – The Growth Rocketship: Shield AI's Takeoff Shows What's Possible in Defensetech

Episode 95 – Drug Pricing: FDA in the Age of Executive Orders and DOGE

Episode 94 – Drug Pricing: 2025 J.P. Morgan Healthcare Conference Takeaways and Outlook

Episode 93 – EU's Digital Operational Resilience Act: What You Should Know and How to Stay Compliant

Episode 92 – UK FinReg Focus Areas in 2025: Sectoral Trends

Episode 91 – UK FinReg Focus Areas in 2025: Retail Markets

Episode 90 – UK FinReg Focus Areas in 2025: Wholesale Markets

Episode 89 – The Growth Rocketship: How BridgeBio's Hub and Spoke Portfolio Strategy Set the Market for the Future of Biotech – Then, Now, and What's Next?

Episode 88 – Drug Pricing: How Might the Trump Administration Transform FDA Enforcement Activities?

Episode 87 – Drug Pricing: What's In the New CMS Medicaid Final Rule?

Episode 86 – Drug Pricing: Takeaways from the Chicago Medicaid Drug Rebate Program Summit

Episode 85 – Drug Pricing: How The Demise of Chevron Deference and Other Litigation May Impact the Pharmaceutical Industry

Episode 84 – Pro Bono: Shabir Kabiri's Remarkable Journey from Afghanistan to Asylum in the US

Episode 83 – Drug Pricing: How Are Payers Responding to the IRA?

Episode 82 – Drug Pricing: Takeaways from the New Orleans Pricing and Contracting USA Conference

Episode 81 – Drug Pricing: A Look Behind the Curtain of the New ASP Reporting Website and Other Data Collection Portals

Episode 80 – Energy & Infrastructure: Why is Energy Tech So Attractive to Venture Capital?

Episode 79 – Pro Bono: Rewilding the Scottish Highlands Through Forest Restoration

Episode 78 – UK FinReg Focus Areas in 2024: ESG

Episode 77 – UK FinReg Focus Areas in 2024: Enforcement Against Individuals

Episode 76 – UK FinReg Focus Areas in 2024: Regulatory Divergence

Episode 75 – UK FinReg Focus Areas in 2024: Enforcement Against Firms

Episode 74 – UK FinReg Focus Areas in 2024: Conduct and Culture

Episode 73 – UK FinReg Focus Areas in 2024: Artificial Intelligence

Episode 72 – UK FinReg Focus Areas in 2024: The Edinburgh Reforms

Episode 71 – Drug Pricing: A Look Ahead at Trends for 2024

Episode 70 – UK FinReg Focus Areas in 2024: Investment Research

Episode 69 – UK FinReg Focus Areas in 2024: Retail Markets – Direction of Travel

Episode 68 – Drug Pricing: Will Agencies Exercise March-In Rights Based on Drug Price?

Episode 67 – PE Views: The Most Pressing Cybersecurity Considerations For Private Equity

Episode 66 – UK FinReg Focus Areas in 2024: Primary Markets Reform

Episode 65 – PE Views: How Can PE Sponsors Promote Transparency and Successful Fund Raise Amid ESG Scrutiny?

Episode 64 – Energy & Infrastructure: How Can Companies Avoid Greenwashing Allegations and ESG Litigation Risks?

Episode 63 – M&A Views: How Should Deal Teams Navigate a Global Crackdown on Restrictive Covenants?

Episode 62 – Has FDA Meaningfully Changed Its Restrictions on Off-Label Communications?

Episode 61 – Drug Pricing: New OIG Guidance Reaffirms the Seven Elements of an Effective Compliance Program

Episode 60 – PE Views: Is the CMA's Focus on Roll-Up Transactions Here to Stay?

Episode 59 – SCOTUS Update: Perez v. Sturgis Secures a Supreme Court Win for Disability Rights

Episode 58 – FDI Developments: M&A Security Screening in Europe's Fragmented FDI Landscape

Episode 57 – Drug Pricing: What Trends Emerged from the 2023 Medicaid Drug Rebate Program Summit?

Episode 56 – M&A Views: Avoiding Buyer's Remorse in M&A Deals

Episode 55 – Insurtech: What Should Startups Do After Receiving FCA Authorization?

Episode 54 – Drug Pricing: Focus on Best Price — CMS Proposed Rule, Inflation Reduction Act

Episode 53 – Energy & Infrastructure: Can Sustainable Finance Fuel the Energy Transition?

Episode 52 – Drug Pricing: Could a Single Reference Price Apply Across a Therapeutic Class?

Episode 51 – Drug Pricing: Final IRA Price Negotiation Guidance – How CMS Addressed the Part D/B Problem

Episode 50 – PE Views: Under New Reforms, Is the Customer Always Right?

Episode 49 – PE Views: Will Greenwashing Rain on the UK PE Parade?

Episode 48 – M&A Views: Will UK-Bound M&A Need to Come to US Terms?

Episode 47 – Real Estate Realities in Europe: Expensive Money and the Power of Private Equity

Episode 46 – PE Views: PE Must Strike the Right Balance With Unions

Episode 45 – Will Insurtech Reach New Heights in 2023?

Episode 44 – PE Views: Private Equity Looks to Share-Based Schemes to Incentivise Non-Managerial Staff

Episode 43 – Energy & Infrastructure: The Drivers and Opportunities of Asia's Digital Infrastructure Boom

Episode 42 – PE Views: Has Rethinking Cannabis Sparked PE Interest?

Episode 41 – PE Views: Why Do Music Deals Sound So Attractive to PE?

Episode 40 – PE Views: Could PE Benefit From the Universal Adoption of "Super Senior" RCFs in Leveraged Financings?

Episode 39 – New FDA Commissioner Dr. Califf: What His Appointment Means for the Regulated Industry and What to Watch for in 2022

Episode 38 – PE Views: How are ESG Regulatory Reforms and Investor Focus Shaping the Market?

Episode 37 – Energy & Infrastructure: What's Behind The Wave of ESG Shareholder Activism?

Episode 36 – Fintech Focus: The Year in Crypto – What Changed and What Comes Next in 2022?

Episode 35 – PE Views: Is Gaming the Next Level for Private Equity?

Episode 34 – Fintech Focus: What's Next for Hong Kong and Singapore in 2022?

Episode 33 – PE Views: How is Creative Collateral Use Changing PE Finance Options?

Episode 32 – PE Views: Will UK IPOs with Dual Class Shares Surface New PE Opportunities?

Episode 31 – PE Views: How is Growth Equity Connecting PE and VC?

Episode 30 – PE Views: Has the Pandemic Increased Whistleblowing Risks?

Episode 29 – Energy & Infrastructure: What's Driving the Oil & Gas Evolution in Europe?

Episode 28 – Energy & Infrastructure: What's the View From Inside the DOE Loan Programs Office?

Episode 27 – Energy & Infrastructure: How Will EP4 Affect Projects in High-Income Countries?

Episode 26 – Energy & Infrastructure: Will the Market Sustain Its Interest in Sustainability-Linked Bonds?

Episode 25 – Fast Track to IPO: Why Are Series A Startups Snatching Topflight CFOs?

Episode 24 – Energy & Infrastructure: How Will the Biden Administration's Goals Affect the Energy Transition?

Episode 23 – Energy & Infrastructure: Renewables Driving Change in the Investment Landscape

Episode 22 – PE Views: Foreign Investment Controls – Are We Seeing a More Nuanced Approach to Private Equity?

Episode 21 – Healthcare Tech: How Are Licensing Agreements Bridging the Industry Divide?

Episode 20 – Healthcare Tech: How Will the FDA Regulatory Framework Adapt to AI?

Episode 19 – Copyright & Brexit: How Will Article 15 of the EU Copyright Directive Affect Publishers and Platforms‪?

Episode 18 – Tech Trends: Has the Tide Turned for Transatlantic Data Transfers Post-Schrems II?

Episode 17 – Copyright & Brexit: Will the UK Copy the EU Directive or Develop Its Own Regime?

Episode 16 – Insolvency Reform: Spotting and Mitigating Future Risk in Supply Relationships

Episode 15 – Healthcare Tech: What Legal Pitfalls Should Tech Companies Avoid As They Jump Into Healthcare?

Episode 14 – Fintech Focus: Crypto in the Crosshairs – What Regulatory Themes Characterized 2020?

Episode 13 – Fintech Focus: How Did Singapore Solidify Its Position as a Leading Fintech Hub in 2020?

Episode 12 – Fintech Focus: Payments During the Pandemic – What Key Legal and Regulatory Themes Emerged During 2020?

Episode 11 – Restructuring in Asia: How Will Chinese Bond Defaults Resolve?

Episode 10 – PE Views: The Lipstick Effect — Why Are Beauty Deals Increasingly Attractive for Private Equity?

Episode 9 – Tech Trends: CCPA and the Next Wave of Data Privacy Regimes

Episode 8 – Corporate Culture: How to Attain Sustainable Change

Episode 7 – Brexit & Financial Services: Preparing for the End of the Transition Period

Episode 6 – Tech Trends: Tech M&A – How Has the Pandemic Changed the Market?

Episode 5 – Insolvency Reform: Termination on Ipso Facto of Supply Contracts

Episode 4 – The ABCs of ESG: How Are Companies Going Beyond the Basics?

Episode 3 – Tech Trends: AI is Here. Now, can we teach the robots ethics and legal compliance?

Episode 2 – Tech Trends: How Does Growth Debt Fuel Startups Between Equity Rounds?

Episode 1 – Tech Trends: IPO or Direct Listing?